Search PubMed⌕ Search

Biomedical subjects

G Mastella

Publications and source records attributed to G Mastella.

At least 127 records · Page 7Linked to original sources

[Italian Cystic Fibrosis Registry: 10 years of activity].

Cystic Fibrosis (CF) is a recessive autosomic genetic disease with an incidence in mediterranean countries of about 1:3500 born alive. In Italy the considerable genetic variability makes it difficult to identify all the homozygous subjects and, consequently, to estimate the incidence of the disease in healthy carriers. The disease is evolutive and affects various systems, most of all the respiratory and gastrointestinal systems. Not many years ago, when the clinical definition of CF was first introduced, average survival did not exceed the pediatric age. Nowadays with ever advancing diagnostic and therapeutical techniques many CF patients survive until an adult age. It is therefore necessary to plan adequate health service interventions so as to satisfy as much as possible the needs of both the patients and their families. To this end data collected since 1.1.1988 by the Italian registry for CF (year of birth, sex, region of birth and residence, diagnosis procedures, results of sweat test, pancreatic insufficiency, DNA analysis, status: alive, dead, lost to follow up) of all the patients, diagnosed in the 18 Reference Centres and the 3 local Centres for CF, have proved to be extremely useful. Since the birth of the Registry on 31.12.1997, data relating to 2458 patients alive on 1.1.1988 and 1159 born during the last ten years, for a total of 3617 subjects (1756 females and 1861 males), have been recorded. As already mentioned a considerable increase in life expectancy of CF patients (from 1988 to 1990 the average age of death was 14 years, from 1994 to 1997 it was 19) and a consequent increase in the percentage of adult patients have been observed.

Adolescent↗

[Practical problems in supply and use of ultrasonic nebulizers at home for aerosol treatment of cystic fibrosis].

With the aim of evaluating the technical and administrative problems which are relevant to the home aerosol therapy through ultrasonic nebulizers in the management of cystic fibrosis (CF), a comparative study was performed on three types of devices. The study was carried out by means of a questionnaire on the basis of an intensive motivation of the users who were enrolled. The questionnaire was given to 36 families involved in the CF management: they were subdivided into 3 groups of twelve, to each one of whom one of the 3 types of devices had been prescribed. Thirty three families, 11 for each group, answered. With regard to the supply of the devices, an enormous delay was observed: on average from 48 to 111 days according to the groups. The major problems of endurance and maintenance were concerning the american nebulizer Devilbiss Ultranebb mod. 99, the highest costs regarded the German nebulizer Klava 5000. The users' comprehensive evaluation of the devices were fairly in accordance to the results concerning their endurance over time. However, the study showed also some defects of compliance in the patients and their families as regard to the disinfection of the instruments as prescribed by the care Center.

Aerosols↗

[Ciprofloxacin: an alternative oral treatment in respiratory Pseudomonas infection in cystic fibrosis].

20 CF patients, aged from 16.5 to 31.7 years, with chronic pulmonary infection due to Pseudomonas, were included in an open trial to study the efficacy of ciprofloxacin on respiratory exacerbation. Ciprofloxacin was given orally at the dose of 1500 mg/die for ten days. 16 patients concluded the entire treatment with clear clinical improvement, based on a score including 11 parameters. There has also been a significant improvement in the pulmonary function tests, and a tendency of Rx score to decrease. 4 patients interrupted the treatment on the fifth day because of clinical inefficacy. There was no increase of Pseudomonas resistance to ciprofloxacin at the end of the treatment; 30 days after no strain of pseudomonas was found resistant. We observed side-effects in 5 patients, but in no case it was necessary to discontinue the treatment. Ciprofloxacin may be considered as a good alternative to the more established antibiotic strategy in the treatment of Pseudomonas lung exacerbations in CF.

Administration, Oral↗

[Chronic suppurative bronchopathy and motility defect of neutrophils: evaluation of an immunomodulating treatment].

Five patients with recurrent infections of the lower respiratory tract, chronic bronchial suppuration and significant defect of polymorphonuclear granulocyte (PMN) motility were studied. Clinical evaluation and in vitro studies of PMN motility were performed before, during and after the treatment with levamisole chlorhydrate (2.5 mg/Kg twice a week). Clinical improvement was obtained in all the patients, together with a significant increase in the chemotactic response of PMN. No side effects were reported. After a follow-up of 7-18 months PMN chemotaxis remained normal in all the patients and a reappearance of respiratory symptoms was observed only in one subject.

Adolescent↗

[Hurler's disease].

Explore the source record for details and available documents.

Humans↗